Tenofovir Alafenamide Fumarate Tablets 25mg (Vemlidy® / ベムリディ錠25mg)

JPY ¥34,400

Japanese Antiviral Chemotherapeutic Agent (Tenofovir Alafenamide Fumarate 25mg). Oral once-daily tablet for suppression of HBV replication in chronic hepatitis B. 30 tablets [bottle, bulk, with desiccant]. Mfd. by Gilead Sciences K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥31,648
10 - 19 12% JPY ¥30,272
20 + 18% JPY ¥28,208
SKU: VML-25-TAB Category:

Description

Product Overview / 商品概要

Vemlidy Tablets 25mg (ベムリディ錠25mg)
Generic: Tenofovir Alafenamide Fumarate / テノホビル アラフェナミドフマル酸塩
Therapeutic Category: Antiviral Chemotherapeutic Agent / 抗ウイルス化学療法剤
Manufactured by: Gilead Sciences K.K. / ギリアド・サイエンシズ株式会社

Composition & Specification / 組成・規格

Active Ingredient: Tenofovir Alafenamide 25mg (as Tenofovir Alafenamide Fumarate 28mg) per tablet / テノホビル アラフェナミド 25mg(テノホビル アラフェナミドフマル酸塩として 28mg)
Additives: Croscarmellose sodium, Lactose hydrate, Magnesium stearate, Microcrystalline cellulose, Yellow ferric oxide, Macrogol 4000, Polyvinyl alcohol (partially saponified), Talc, Titanium oxide / クロスカルメロースナトリウム、乳糖水和物、ステアリン酸マグネシウム、結晶セルロース、黄色三二酸化鉄、マクロゴール 4000、ポリビニルアルコール(部分けん化物)、タルク、酸化チタン
Appearance: Yellow film-coated tablet, diameter 8mm, thickness 4mm, weight 208mg, identification code GSI·25
外観: 黄色のフィルムコーティング錠、直径 8mm、厚さ 4mm、重さ 208mg、識別コード GSI・25

Indications / 効能効果

EN: Suppression of hepatitis B virus (HBV) replication in chronic hepatitis B disease with confirmed hepatic dysfunction associated with HBV proliferation
JA: B 型肝炎ウイルスの増殖を伴い肝機能の異常が確認された B 型慢性肝疾患における B 型肝炎ウイルスの増殖抑制

Dosage and Administration / 用法用量

EN: The usual adult dose is 25mg of tenofovir alafenamide administered orally once daily.
JA: 通常、成人にはテノホビル アラフェナミドとして 1 回 25mg を 1 日 1 回経口投与する。

Contraindications / 禁忌

EN: (1) Patients with a history of hypersensitivity to any component of this product. (2) Patients receiving rifampicin or St. John’s Wort (Hypericum perforatum)-containing products.
JA: (1)本剤の成分に対し過敏症の既往歴のある患者。(2)リファンピシン、セイヨウオトギリソウ(セント・ジョーンズ・ワート)含有食品を投与中の患者。

Regulatory Information / 規制情報

Approval No.: 22800AMX00732000
Sales Started: February 2017 / 2017年2月
Classification Code: 87625
Storage: Store at room temperature / 室温保存
Shelf Life: Bottle: 36 months, PTP blister: 24 months / 瓶:36ヵ月、PTP:24ヵ月

Packaging / 包装

Main Package (for sale): 30 tablets [bottle, bulk, with desiccant] / 30 錠[瓶、バラ、乾燥剤入り]
Other Available Packages (by special order): 30 tablets [bottle, bulk, with desiccant], 28 tablets [14 tablets (PTP) x 2, with desiccant]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Tenofovir Alafenamide Fumarate Tablets 25mg (Vemlidy® / ベムリディ錠25mg)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Tenofovir Alafenamide Fumarate Tablets 25mg (Vemlidy®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.